Title:A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?
Volume: 12
Issue: 1
Author(s): Wala Ben Kridis, Nabil Toumi, Hadil Chaari, Afef Khanfir, Kamel Ayadi, Hassib Keskes, Tahia Boudawara, Jamel Daoud and Mounir Frikha
Affiliation:
Keywords:
Chemotherapy, ewing sarcoma, malignant bone tumors, prognostic factor, therapeutic strategies, treatment.
Abstract: Background: The Ewing sarcoma (ES) represents 10 to 15% malignant bone tumors and 40
to 45% pediatric malignant bone tumors. The aim of this review is to clarify the therapeutic results and
prognostic factors of this entity.
Methods: A systematic review of the literature was performed. Studies focused on the management of
ES were considered for inclusion.
Result: ES represents a model of multidisciplinary approach. The optimization of ES multimodality
therapeutic strategies has resulted from the efforts of several national and international groups in Europe
and North America and from cooperation between the pediatric and medical oncologists. The overall 5-
year survival of Ewing localized tumors was 70% versus 30% in metastatic ES.
Conclusion: The treatment of ES includes neoadjuvant and adjuvant chemotherapies with surgery
and/or radiotherapy for control of the primary site and possible metastatic disease. The role of high-dose
chemotherapy is still debated.
